Cleared Traditional

WEE BAG O'MERCURY (K946194) - FDA 510(k) Clearance

Class II Ophthalmic device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K946194 · Microsurgical Technology, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1995
Decision
69d
Days
Class 2
Risk

K946194 is an FDA 510(k) clearance for the WEE BAG O'MERCURY. Classified as Applicator, Ocular Pressure (product code LCC), Class II - Special Controls.

Submitted by Microsurgical Technology, Inc. (Kirkland, US). The FDA issued a Cleared decision on February 27, 1995 after a review of 69 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4610 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Microsurgical Technology, Inc. devices

Submission Details

510(k) Number K946194 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 20, 1994
Decision Date February 27, 1995
Days to Decision 69 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
41d faster than avg
Panel avg: 110d · This submission: 69d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LCC Applicator, Ocular Pressure
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4610
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.